Proof of Usefulness Report

Octimet Oncology

Analysis completed on 2/8/2026

+18
Proof of Usefulness Score
You're In Business

Octimet Oncology NV was a legitimate Belgian biotech company founded in 2016 that raised significant Series A funding (€11.3M) to develop MET kinase inhibitors (OMO-1). However, the company appears to have ceased independent operations around 2020, with its key assets licensed to DeuterOncology NV and Shanghai Allist Pharmaceuticals. The submission contains severe inaccuracies and 'red flag' claims, such as stating 'most people have used my product' (false for a clinical-stage cancer drug) and identifying the audience as 'everyone.' The submitter 'CrimsonKeeper' does not appear to be a company principal. While the underlying technology has high potential utility, the project seems dormant, and the submission is of extremely low quality and credibility.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+75
Audience Reach Impact+5
Technical Innovation+50
Evidence Of Traction+5
Market Timing Relevance+20
Functional Completeness+10
Subtotal+15.875
Usefulness Multiplierx1.12
Final Score+18

Project Details

Project URL
octimet.com
Description
OCTIMET oncology was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen. Headed by Dr. Timothy Perera (CEO), OCTIMET has licensed highly selective MET kinase inhibitors with clean safety profiles from Janssen Pharmaceutica and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents using biomarker defined intelligent patient selection.

Algorithm Insights

Market Position
Growing utility with room for optimization
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline